Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtech Industry Groups Spend Millions In 2019 Lobbying For Device-Tax Repeal – And Much More

Executive Summary

Industry trade groups spend millions of dollars and walk thousands of steps in the halls of the US Congress each year to persuade legislators and their staff to support votes on device-tax repeal, Medicare payment reform, and other issues. Using lobbying reports downloaded by a public interest group, Medtech Insight has analyzed what industry spent and paid out to hire legislative experts to lobby Congress in the first half of 2019, and which topics they lobbied for the most.

You may also be interested in...



Industry Advocacy Group Goes Global After Device Tax Repeal

After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.

AdvaMed Chair: Another Device Tax Moratorium More Likely Than A Full Repeal

As the top medtech lobby groups continue to push for a permanent repeal of the medical device excise tax, one of their top lobbyists and medtech executives says it’s far more likely they will see another multiyear moratorium considering the political reality.

Industry, AJC Duke It Out In Georgia Over Ethylene Oxide Risk

While AdvaMed has remained relatively quiet over the recent closures of ethylene oxide (EtO) sterilization facilities, the medical device industry advocacy group is taking on critics in Georgia, where two facilities have been paused to upgrade their operations to reduce EtO emissions. Critics – including the Atlanta Journal-Constitution’s editorial board – say the chemical is associated with increased risk for cancer for nearby residents, but AdvaMed and its supporters say there’s no evidence to back that up.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel